SCHEMBL4116141

SCHEMBL4116141

Nc1ccc(C(=O)NCCC2C(Nc3nccc(N4CCCCCC4)n3)CCCN2C2CCCCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.40
▸ JAK2 O60674 7/20 0.37
▸ JAK1 P23458 7/20 0.37
▸ TYK2 P29597 7/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ HRH4 Q9H3N8 3/20 0.37
▸ CCNK O75909 1/20 0.36
▸ CDK12 Q9NYV4 1/20 0.36
▸ HDAC3 O15379 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ RAF1 P04049 1/20 0.35
▸ HSPB1 P04792 1/20 0.35
▸ LYN P07948 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ HSD11B1 P28845 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037748 0.92 CXCR4 (0.39) CXCR4JAK2JAK1TYK2JAK3
SCHEMBL13696563 0.92 CXCR4 (0.39) CXCR4JAK2JAK1TYK2JAK3
SCHEMBL4110319 0.89 CXCR4 (0.40) CXCR4HRH4CCNKCDK12SYK
SCHEMBL4104358 0.88 CXCR4 (0.40) CXCR4JAK2JAK1TYK2JAK3
SCHEMBL4116308 0.88 HRH4 (0.42) CXCR4JAK2JAK1TYK2JAK3
SCHEMBL4116420 0.87 CXCR4 (0.43) CXCR4HRH4CCNKCDK12HSD11B1
SCHEMBL13696562 0.87 ALDH1A1 (0.40) CXCR4JAK3ALDH1A1SMN1; SMN2
SCHEMBL2011688 0.87 ALDH1A1 (0.40) CXCR4JAK3ALDH1A1SMN1; SMN2
SCHEMBL13696561 0.85 CXCR4 (0.43) CXCR4HSD11B1SMN1; SMN2
SCHEMBL4116233 0.85 CXCR4 (0.43) CXCR4HSD11B1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 CXCR4 1/4885JAK2 115/4885JAK1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback